Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin
Issue Date
2016-10-27xmlui.metadata.dc.contributor.email
joruiz.trabajo@gmail.comMetadata
Show full item recordCitation
1. Gomes C, Martínez-puchol S, Palma N, Horna G, Ruiz-roldán L, Pons MJ, et al. Critical Reviews in Microbiology Macrolide resistance mechanisms in Enterobacteriaceae : Focus on azithromycin Macrolide resistance mechanisms in Enterobacteriaceae : Focus on azithromycin. Crit Rev Microbiol [Internet]. Informa Healthcare USA, Inc; 2016;0(0):000. Available from: http://dx.doi.org/10.3109/1040841X.2015.1136261Publisher
Taylor & FrancisJournal
Critical Reviews in MicrobiologyDOI
10.3109/1040841X.2015.1136261Additional Links
https://www.tandfonline.com/doi/full/10.3109/1040841X.2015.1136261Abstract
From its introduction in 1952 onwards, the clinical use of macrolides has been steadily increasing, both in human and veterinary medicine. Although initially designed to the treatment of Grampositive microorganisms, this antimicrobial family has also been used to treat specific Gram-negative bacteria. Some of them, as azithromycin, are considered in the armamentarium against Enterobacteriaceae infections. However, the facility that this bacterial genus has to gain or develop mechanisms of antibiotic resistance may compromise the future usefulness of these antibiotics to fight against Enterobacteriaceae infections. The present review is focused on the mechanisms of macrolide resistance, currently described in Enterobacteriaceae.Type
info:eu-repo/semantics/articleRights
info:eu-repo/semantics/openAccessLanguage
engISSN
1040-841X1549-7828